41 completed, 7 recruiting, 6 terminated, 3 unknown. 60 Phase 2, 12 Phase 3, 9 Phase 1.
Follow Myelitis: new trials by email Literature Review of Myelitis trials Research Report on Myelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection, Dolutegravir (DTG) - HTLV-1 Infection, HTLV I Associated Myelopathies | Phase 2 | Recruiting | Carlos Brites | 146 | 2026-05-07 | 2026-06-02 |
| Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 2 (nOPV2), Placebo (Sterile Water) - Poliomyelitis | Phase 2 | Recruiting | PATH | 675 | 2025-11-11 | 2026-01-09 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose, VLP-Polio medium dose, VLP-Polio high dose - Poliomyelitis | Phase 1 / Phase 2 | Active not recruiting | CanSino Biologics Inc. | 480 | 2024-12-19 | 2026-08-06 |
| Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2), Novel oral poliomyelitis vaccine type 3 (nOPV3) - Poliomyelitis | Phase 1 / Phase 2 | Recruiting | PATH | 2400 | 2024-11-20 | 2025-06-03 |
| Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2024-10-02 | 2024-10-01 |
| Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3), Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3) - Poliomyelitis | Phase 2 | Recruiting | PATH | 1532 | 2023-12-05 | 2026-05-11 |
| Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1), Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1) - Poliomyelitis | Phase 2 | Completed | PATH | 2232 | 2023-03-27 | 2026-09-25 |
| Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC Vibegron - Neurogenic Detrusor Overactivity | Phase 2 / Phase 3 | Recruiting | Urovant Sciences GmbH | 71 | 2022-10-12 | 2026-06-15 |
| Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis Q-Cells - Transverse Myelitis | Phase 1 / Phase 2 | Recruiting | Q Therapeutics, Inc. | 9 | 2022-09-20 | 2026-07-21 |
| Immunogenicity nOPV2 With and Without bOPV Novel monovalent oral poliovirus vaccine type 2 (nOPV2), Bivalent oral poliovirus vaccine (bOPV) - Poliomyelitis | Phase 2 | Completed | Centers for Disease Control and Prevention | 795 | 2021-02-08 | 2024-10-04 |
| Clinical Trial of Novel OPV2 Vaccine novel oral polio type 2 vaccine (nOPV2), Placebo - Poliomyelitis | Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 330 | 2020-09-21 | 2022-08-30 |
| Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally Inactivated poliovirus vaccine in reduced doses - Polio | Phase 2 | Completed | Instituto Nacional de Saúde, Mozambique | 382 | 2020-08-06 | 2024-01-31 |
| A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Eculizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 5 | 2020-01-14 | 2024-09-25 |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2019-11-01 | 2019-09-06 |
| Rituximab for HTLV-1-associated Myelopathy Rituximab - HTLV-1-associated Myelopathy | Phase 2 | Unknown | First Affiliated Hospital of Fujian Medical University | 100 | 2019-08-15 | 2022-04-19 |
| A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine nOPV2 (monovalent oral polio vaccine) - Poliomyelitis | Phase 2 | Completed | Fidec Corporation | 1025 | 2018-12-04 | 2024-01-19 |
| A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates Novel OPV2 candidate 1, Novel OPV2 candidate 2, Placebo - Poliomyelitis | Phase 2 | Completed | Pierre Van Damme | 250 | 2018-10-22 | 2021-10-15 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
Showing 20 of 60. Sign in to see all of them.
Poliomyelitis (43) · Tetanus (21) · Diphtheria (20) · Hepatitis B (18) · Haemophilus Infections (16) · Whooping Cough (11) · Paraparesis, Tropical Spastic (7) · Myelitis, Transverse (5) · Postpoliomyelitis Syndrome (3) · Encephalitis (2) · HTLV-I Infections (2) · Neuromyelitis Optica (2) · Spinal Cord Injuries (2) · Virus Diseases (2)
Central Nervous System Diseases (60) · Central Nervous System Infections (60) · Infections (60) · Nervous System Diseases (60) · Neuroinflammatory Diseases (60) · Spinal Cord Diseases (59) · RNA Virus Infections (53) · Virus Diseases (52) · Neuromuscular Diseases (47) · Enterovirus Infections (46) · Picornaviridae Infections (46) · Bacterial Infections (21) · Bacterial Infections and Mycoses (21) · Clostridium Infections (21)
Poliovirus Vaccine, Inactivated (9) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (9) · 13-valent pneumococcal vaccine (3) · Vaccines, Combined (3) · Immunoglobulins, Intravenous (2) · Rabies Vaccines (2) · Tetanus Toxoid (2) · 10-valent pneumococcal vaccine (1) · 4-Aminopyridine (1) · Cyclosporine (1) · DTaP-IPV-HB-PRP-T vaccine (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate (1) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (1) · Hepatitis B Vaccines (1)
GlaxoSmithKline (10) · LG Chem (5) · Sanofi Pasteur, a Sanofi Company (5) · PATH (4) · Imperial College London (3) · Centers for Disease Control and Prevention (2) · Institute of Medical Biology, Chinese Academy of Medical Sciences (2) · Jiangsu Province Centers for Disease Control and Prevention (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Alexion Pharmaceuticals, Inc. (1) · Buckinghamshire Healthcare NHS Trust (1) · CanSino Biologics Inc. (1) · Carlos Brites (1) · Chinese Academy of Medical Sciences (1) · Fidec Corporation (1)
United States (10) · Canada (7) · China (7) · Panama (5) · Philippines (5) · Poland (5) · Bangladesh (4) · Finland (4) · Germany (4) · United Kingdom (4) · Dominican Republic (3) · Belgium (2) · Denmark (2) · Italy (2) · Japan (2)
Amanda Wilkinson, PhD (1) · Benjamin Greenberg, MD (1) · Carlos Brites, MD, PhD (1) · Dang D Anh, PhD (1) · Edison Alberto, MD (1) · Edna Viegas, MD,PhD (1) · Elisabeth Farbu, MD, PhD (1) · Fengcai Zhu, Master (1) · Graham P Taylor (1) · Graham P Taylor, FRCP (1) · Graham P Taylor, MD (1) · Ingrid Kromann (1) · Janet Owens-Grillo (1)
PMID 22153001, PMID 28340322, PMID 32867698, PMID 40318674, PMID 16984654, PMID 21372751, PMID 22158682, PMID 22720101, PMID 23241989, PMID 24346596, PMID 24884681, PMID 25043278, PMID 25540274, PMID 26719058, PMID 28419204, PMID 28454674, PMID 29304199, PMID 30249424, PMID 33308427, PMID 33308429, PMID 33351072, PMID 36332645, PMID 36495882, PMID 37178706, PMID 38218668, PMID 39186315
2009 (1), 2014 (1), 2018 (1), 2019 (1)